MEDCL MedinCell SA

MedinCell receives “Prime” ISS ESG rating as a recognition of the embedment of Corporate Social Responsibility across the Company

MONTPELLIER, France--(BUSINESS WIRE)--

MedinCell (Paris:MEDCL):

“This recognition is a tribute to MedinCell efforts and performance.” said Christophe Douat, CEO of MedinCell. “Strong ESG performance is an increasingly important factor in attracting investors and the Prime status received from ISS ESG is a valuable guide for those seeking to identify companies that are driving positive change. We have always considered that our sustainable company model is inseparable from our raison d’être.”

MedinCell began to formalize its corporate and social responsibility with the inclusion of its raison d’être in its statutes in 2019: Our mission is to contribute to the improvement and protection of the health of populations across the world. The fair sharing of the value created with all our employees is the foundation of our business model. The sustainability of MedinCell is an essential condition for achieving our objectives. In 2022, the Company established an ESG committee at its board. Other achievements include the embedment of ESG culture and the implementation of quantitative ESG objectives.

EN
23/02/2023

Underlying

MEDCLMedinCell SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MedinCell SA

Oscar Haffen Lamm
  • Oscar Haffen Lamm
MEDCL MEDINCELL SA

Medincell: Uzedy TRx shows strong demand, mdc-TJK NDA filing expected ...

Yesterday Teva presented its Q1'25 results, with Uzedy sales for the quarter coming in at USD39m (+160% YoY). While beating Teva's css (USD32.5m, +20%), sales appeared relatively flattish compared Q4 (USD43m), which could be attributed to calendar effects and stock adjustments. We remain optimistic

05/08/25 May 8, 2025 1 EN
Oscar Haffen Lamm
  • Oscar Haffen Lamm
MEDCL MEDINCELL SA

MedinCell and iM4TB to initiate development of a Macozinone LAI in tub...

MedinCell and iM4TB to initiate the development of a LAI version of Macozinone for the treatment of tuberculosis, a potential first-in-class which has shown promising results in past phase 1/2 studies. The value add of a long-acting formulation in tuberculosis is clear, considering that current tre

04/23/25 April 23, 2025 1 EN
Oscar Haffen Lamm
  • Oscar Haffen Lamm
MEDCL MEDINCELL SA

MedinCell: patient and HCP survey highlight key features of its olanza...

Teva presented early clinical feedback from a patient and healthcare professional survey regarding its olanzapine LAI TEV'749 (mdc-TJK), in particular around important schizophrenia treatment factors — dosing schedule, initiation regimen, SC administration, post-injection monitoring requirements an

04/01/25 April 1, 2025 1 EN
 PRESS RELEASE
Free
MEDCL MEDINCELL SA

MedinCell : Information relative au nombre d’actions composant le capi...

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: MedinCell (Paris:MEDCL) : Place de cotation : Euronext Paris, Compartiment B Code ISIN : FR0004065605 Date Nombre de titres composant le capital en circulation Nombre total de droits de vote Total brut (1) Total net (2) 28 février 2025 33 065 845 44 689 724 44 684 224 (1) Le nombre de droits de vote bruts (ou droits de vote “théoriques”) sert de base de calcul pour les franchissements de seuil. Conformément à l’article 223-11 du Règlement Général de l’AMF, ce nombre est calculé sur la base de l’ensembl...

March 7, 2025 1 FR
 PRESS RELEASE
Free
MEDCL MEDINCELL SA

Medincell renforce son Conseil d’administration pour accompagner sa cr...

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: Medincell (Paris:MEDCL): Pascal Touchon rejoint le Conseil d’administration : 40 ans d'expérience internationale dans l'industrie biopharmaceutique à des postes de direction générale et stratégique et en tant que membre de conseils d'administration de sociétés américaines et européennes, Ancien Directeur Mondial de la Stratégie et du Business Development puis de l’activité globale Cell & Gene de Novartis Oncology, il a dirigé le développement et le lancement international de la toute première thérapie cellulaire et génique approuvée...

March 6, 2025 1 FR

ResearchPool Subscriptions

Get the most out of your insights

Get in touch